In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Banyu Pharmaceutical Co. Ltd.

Division of Merck & Co. Inc.

Latest From Banyu Pharmaceutical Co. Ltd.

The Rise Of Japanese Pharma Dealmakers

Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.

BioPharmaceutical Middle East and Africa

The Rise of Regional Dealmaking

Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.

BioPharmaceutical Middle East and Africa

Schering-Plough: What Went Wrong, What to Do

CEO Fred Hassan faults decentralization and financial over-management for much of Schering's trouble--including its inability to fix its manufacturing problems, its lack of oversight over its sales force, and its inadequate response to the competitive threat from Roche. Cutting costs further--as some analysts looking for short-term earnings growth would like to see--won't help. Instead, Hassan's investing-particularly in marketing-oriented clinical studies.

BioPharmaceutical Strategy

Merck/Banyu: A Harbinger of More Western-Japanese Deals?

It's now official: the Japanese drug industry is succumbing to consolidation. The only question is whether the consolidators will be Western companies or the Japanese themselves. The latest and least unexpected transaction: Merck & Co. Inc.'s takeover of the remaining 49% of Banyu Pharmaceutical Co. Ltd. it didn't already own, in a $1.52 billion tender offer.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Alias(es)
  • Merck Banyu
  • Nippon Merck-Banyu
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Haruhiko Hirate, Pres.
  • Contact Info
  • Banyu Pharmaceutical Co. Ltd.
    Phone: (81) 3-5203-8111
    2-2-3, Nihombashi-Honcho 2-chome
    Tokyo, 103-8416